BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Business

  Five Top CEOs to Watch in 2022

  Several CEOs have stood out from their peers throughout the past year, winning recognition from the Healthcare Technology Report. BioSpace looks at five of these leaders.

  February 23, 2022

   · 

  5 min read

   · 

  Alex Keown
• 

  Drug Development

  Money on the Move: February 16–22

  More biotech companies turn to private investors as the market churns volatile for life sciences. Here’s who’s scooping up the cash this week.

  February 23, 2022

   · 

  3 min read

   · 

  Kate Goodwin
• 

  Business

  Mnemo Taps Pharma Veteran LaCaze in Quest to Become Global Leader

  Robert LaCaze is taking over the reins of Mnemo Therapeutics with the goal of overcoming key challenges in CAR-T therapies and driving the company’s lead assets into the clinic.

  February 23, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Why Communication Skills Are So Important In Pharma

  Effective communication skills are vital for success in the pharma industry. Here are some tips to help you improve your communication skills.

  February 23, 2022

   · 

  5 min read

   · 

  Mishayl Hanan
• 

  Business

  Three Biopharma Companies Bolster Leadership Teams

  Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.

  February 23, 2022

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Biopharma Giants Make Big Manufacturing Commitments

  Intellia announced a lease agreement to develop a 140,000 square-foot manufacturing facility in Waltham, MA, while Moderna and Thermo Fisher Scientific sign a long-term deal.

  February 23, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Drug Development

  Global Roundup: NuCana’s Biliary Tract Cancer Drug, Charles River, Noema and More

  Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

  February 23, 2022

   · 

  6 min read

   · 

  Alex Keown
• 

  Business

  Veru/Lilly Aim to Fill Gap in Second-Line Metastatic Breast Cancer Therapy

  Veru’s enobosarm shows good proof of concept data even when 90% of patients have failed first-line therapies.

  February 23, 2022

   · 

  4 min read

   · 

  Gail Dutton
• 

  Drug Development

  Kodiak Fails to See Endpoint vs. Regeneron’s Eylea in Wet AMD

  Shares of Kodiak Sciences plunged nearly 70% in premarket trading after its Phase II/III study of KSI-301 failed to demonstrate non-inferior visual acuity gains compared to Regeneron’s Eylea.

  February 23, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Drug Development

  Moderna Cleared to Bring RSV Vaccine to Pivotal Phase III Trial

  The DSMB endorsed the use of mRNA-1345 for the Phase III ConquerRSV study following positive preliminary Phase II data that demonstrates the vaccine’s safety profile.

  February 23, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN